Enhancement of antioxidant defense mechanism by pitavastatin and rosuvastatin on obesity-induced oxidative stress in Wistar rats

Toxicology Mechanisms and Methods

Volumn 22, Issue 1, 2012, Pages 67-73

  Ansari, Javed A ^a   Bhandari, Uma ^a   Haque, S E ^a   Pillai, K K ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Apolipoprotein B; glutathione; high density lipoprotein; lipid peroxides; triglycerides

Indexed keywords

APOLIPOPROTEIN B; CATALASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; LIPID PEROXIDE; PITAVASTATIN; ROSUVASTATIN; SUPEROXIDE DISMUTASE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; LIPID DIET; LIPID PEROXIDATION; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-OBESITY AGENTS; ANTIOXIDANTS; APOLIPOPROTEINS B; CHOLESTEROL, HDL; DISEASE MODELS, ANIMAL; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LACTONES; LIPID PEROXIDES; MYOCARDIUM; OBESITY; OXIDATIVE STRESS; PYRIMIDINES; QUINOLINES; RATS; RATS, WISTAR; SULFONAMIDES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 83455253508     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2011.603391     Document Type: Article

References (51)

1. André A, Gonthier MP. 2010. The endocannabinoid system: Its roles in energy balance and potential as a target for obesity treatment. Int J Biochem Cell Biol 42:1788-1801.
2. Aoki T, Yoshinaka Y, Yamazaki H, Suzuki H, Tamaki T, Sato F, Kitahara M, Saito Y. 2002. Triglyceride-lowering effect of pitavastatin [corrected] in a rat model of postprandial lipemia. Eur J Pharmacol 444:107-113.
3. Bhandari U, Kumar V, Khanna N, Panda BP. 2010. The effect of high fat diet-induced obesity on cardiovascular toxicity in wistar albino rats. Hum Exp Toxicol DOI: 10.1177/0960327110389499 (In press).
4. Calberg I, Mannerviek B. 1975. Glutathione reductase levels in rat brain. J Biol Chem 250:5475-5480.
5. Caner M, Dogruman H, Taskin E, Kandil A, Demirci C. 2005. Effects of orlistat and its relationship with nitric oxide in the small intestinal mucosa. Chin J Physiol 48:217-222.
6. Carmiel-Haggai M, Cederbaum AI, Nieto N. 2005. A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. FASEB J 19:136-138.
7. Claiborne A. 1985. Catalase activity. In: Greenwald RA (ed). CRC Handbook of methods in oxygen radical research. CRC Press, Boca Raton pp 283-284.
8. Dixon JB. 2010. The effect of obesity on health outcomes. Mol Cell Endocrinol 316:104-108.
9. Ellman GL. 1959. Tissue sulfhydryl groups. Arch Biochem Biophys 82:70-77.
10. Habig WH, Pabst MJ, Jakoby WB. 1974. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 249:7130-7139.
11. Han LK, Sumiyoshi M, Zhang J, Liu MX, Zhang XF, Zheng YN, Okuda H, Kimura Y. 2003. Anti-obesity action of Salix matsudana leaves (Part 1). Anti-obesity action by polyphenols of Salix matsudana in high fat-diet treated rodent animals. Phytother Res 17:1188-1194.
12. Ho TF. 2009. Cardiovascular risks associated with obesity in children and adolescents. Ann Acad Med Singap 38:48-49.
13. Hsu CL, Yen GC. 2007. Effect of gallic acid on high fat diet-induced dyslipidaemia, hepatosteatosis and oxidative stress in rats. Br J Nutr 98:727-735.
14. Husain K, Mejia J, Lalla J, Kazim S. 2005. Dose response of alcoholinduced changes in BP, nitric oxide and antioxidants in rat plasma. Pharmacol Res 51:337-343.
15. Ishihara Y, Ohmori K, Mizukawa M, Hasan AU, Noma T, Kohno M. 2010. Beneficial direct adipotropic actions of pitavastatin in vitro and their manifestations in obese mice. Atherosclerosis 212:131-138.
16. Izawa S, Inoue Y, Kimura A. 1996. Importance of catalase in the adaptive response to hydrogen peroxide: Analysis of acatalasaemic Saccharomyces cerevisiae. Biochem J 320:61-67.
17. Juul K, Tybjaerg-Hansen A, Marklund S, Heegaard NH, Steffensen R, Sillesen H, Jensen G, Nordestgaard BG. 2004. Genetically reduced antioxidative protection and increased ischemic heart disease risk: The Copenhagen City Heart Study. Circulation 109:59-65.
18. Kostapanos MS, Milionis HJ, Filippatos TD, Nakou ES, Bairaktari ET, Tselepis AD, Elisaf MS. 2007. A 12-week, prospective, openlabel analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther 29:1403-1414.
19. Kumai T, Oonuma S, Matsumoto N, Takeba Y, Taniguchi R, Kamio K, Miyazu O, Koitabashi Y, Sekine S, Tadokoro M, Kobayashi S. 2004. Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia. Life Sci 74:2129-2142.
20. Lee J, Song KS, Kang J, Lee SH, Lee J. 2009. New trends in medicinal chemistry approaches to antiobesity therapy. Curr Top Med Chem 9:564-596.
21. Liou W, Chang LY, Geuze HJ, Strous GJ, Crapo JD, Slot JW. 1993. Distribution of CuZn superoxide dismutase in rat liver. Free Radic Biol Med 14:201-207.
22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
23. Ludman A, Venugopal V, Yellon DM, Hausenloy DJ. 2009. Statins and cardioprotection-more than just lipid lowering? Pharmacol Ther 122:30-43.
24. Marklund S, Marklund G. 1974. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47:469-474.
25. Saka M, Obata K, Ichihara S, Cheng XW, Kimata H, Noda A, Izawa H, Nagata K, Yokota M. 2006. Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin: potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway. Clin Exp Pharmacol Physiol 33: 1164-1171.
26. Miersch S, Sliskovic I, Raturi A, Mutus B. 2007. Antioxidant and antiplatelet effects of rosuvastatin in a hamster model of prediabetes. Free Radic Biol Med 42:270-279.
27. Mohandas J, Marshall JJ, Duggin GG, Horvath JS, Tiller DJ. 1984. Low activities of glutathione-related enzymes as factors in the genesis of urinary bladder cancer. Cancer Res 44:5086-5091.
28. Mohn A, Catino M, Capanna R, Giannini C, Marcovecchio M, Chiarelli F. 2005. Increased oxidative stress in prepubertal severely obese children: Effect of a dietary restriction-weight loss program. J Clin Endocrinol Metab 90:2653-2658.
29. Mutlu-Türkoglu U, Oztezcan S, Telci A, Orhan Y, Ayka̧-Toker G, Sivas A, Uysal M. 2003. An increase in lipoprotein oxidation and endogenous lipid peroxides in serum of obese women. Clin Exp Med 2:171-174.
30. Myara I, Alamowitch C, Michel O, Heudes D, Bariety J, Guy-Grand B, Chevalier J. 2003. Lipoprotein oxidation and plasma vitamin E in nondiabetic normotensive obese patients. Obes Res 11:112-120.
31. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. 2005. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 28:2728-2732.
32. Noji Y, Higashikata T, Inazu A, Nohara A, Ueda K, Miyamoto S, Kajinami K, Takegoshi T, Koizumi J, Mabuchi H; Hokuriku NK-104 Study Group. 2002. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 163:157-164.
33. Ohkawa H, Ohishi N, Yagi K. 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351-358.
34. Olusi SO. 2002. Obesity is an independent risk factor for plasma lipid peroxidation and depletion of erythrocyte cytoprotectic enzymes in humans. Int J Obes Relat Metab Disord 26:1159-1164.
35. Pagotto U, Vanuzzo D, Vicennati V, Pasquali R. 2008. Pharmacological therapy of obesity. G Ital Cardiol (Rome) 9:83-93.
36. Park Sungha, Kang Hyun-Jae, Rim Se-Joong, Ha Jong-Won, Oh Byung-Hee, Chung Namsik, and Cho Seung-Yun. 2005. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in korean patients with hypercholesterolemia. Clin Ther 27:1074-1082.
37. Powers SK, DeRuisseau KC, Quindry J, Hamilton KL. 2004. Dietary antioxidants and exercise. J Sports Sci 22:81-94.
38. Prakash J, Gupta SK, Kochupillai V, Singh N, Gupta YK, Joshi S. 2001. Chemopreventive activity of Withania somnifera in experimentally induced fibrosarcoma tumours in Swiss albino mice. Phytother Res 15:240-244.
39. Reisin E, Ebenezer PJ, Liao J, Lee BS, Larroque M, Hu X, Aguilar EA, Morse SA, Francis J. 2009. Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese zucker rats fed with an atherogenic diet. Am J Med Sci 338:301-309.
40. Rizvi F, Iftikhar M, George JP. 2003. Beneficial effects of fish liver preparations of sea bass (Lates calcarifer) versus gemfibrozil in high fat diet-induced lipid-intolerant rats. J Med Food 6:123-128.
41. Saito Yasushi, Yamada Nobuhiro, Teramoto Tamio, Itakura Hiroshige, Hata Yoshiya, Nakaya Noriaki, Mabuchi Hiroshi, Tushima Motoo, Sasaki Jun, Ogawa Nobuya, Goto Yuichiro. 2002. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 162:373-379.
42. Silver AE, Beske SD, Christou DD, Donato AJ, Moreau KL, Eskurza I, Gates PE, Seals DR. 2007. Overweight and obese humans demonstrate increased vascular endothelial NAD(P)H oxidasep47( phox) expression and evidence of endothelial oxidative stress. Circulation 115:627-637.
43. Sowers JR. 1998. Obesity and cardiovascular disease. Clin Chem 44:1821-1825.
44. Susic D, Varagic J, Ahn J, Slama M, Frohlich ED. 2003. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol 42:1091-1097.
45. Vincent HK, Powers SK, Dirks AJ, Scarpace PJ. 2001. Mechanism for obesity-induced increase in myocardial lipid peroxidation. Int J Obes Relat Metab Disord 25:378-388.
46. Vincent HK, Innes KE, Vincent KR. 2007. Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity. Diabetes Obes Metab 9:813-839.
47. Watson Angela M., Poloyac Samuel M., Howard Georgette,,and Blouin Robert A. 1999. Effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the Ob/Ob mouse. Drug Metab Dispos 27:695-700.
48. Weidig P, McMaster D, Bayraktutan U. 2004. High glucose mediates pro-oxidant and antioxidant enzyme activities in coronary endothelial cells. Diabetes Obes Metab 6:432-441.
49. Yesilbursa D, Serdar Z, Serdar A, Sarac M, Coskun S, Jale C. 2005. Lipid peroxides in obese patients and effects of weight loss with orlistat on lipid peroxides levels. Int J Obes (Lond) 29:142-145.
50. Yoshioka Keiji, Murakami Yumi, Ego Kyoko, Nakajima Yasuhiro. 2010. Effect of pitavastatin on serum high-molecular weight (HMW) adiponectin to total adiponectin ratio in type 2 diabetic patients. Diabetes & Metabolic Syndrome. Clin Res Rev 4:95-96.
51. Zambarakji Hadi J., Nakazawa Toru, Connolly Edward, Lane Anne Marie, Mallemadugula Sreedevi, Kaplan Michael, Michaud Norman, Hafezi-Moghadam Ali, Gragoudas Evangelos S., Miller Joan W. 2006. Dose-dependent effect of pitavastatin on VEGF and angiogenesis in a mouse model of choroidal neovascularization. Invest Ophthalmol Vis Sci 47:2623-2631.